USFDA - HealthQuill

GSK Plc. and Spero Therapeutics have stopped their combined trial of an investigational oral treatment for urinary tract infections after the study achieved its goal on efficacy.

GSK, Sepro end trial for oral drug to treat urinary tract infections

HQ Team May 28, 2025: GSK Plc. and Spero Therapeutics have stopped their combined trial of an investigational oral treatment for urinary tract.

by HealthQuill
May 28, 2025
0 Comments

The US Food and Drug Administration has granted marketing access to Fujirebio Diagnostics, Inc.’s blood test to diagnose Alzheimer’s disease, the first such approval in the country.

Drugs Health Pharma

Simple blood test to detect Alzheimer’s disease gets US regulator’s nod

HQ Team May 18, 2025: The US Food and Drug Administration has granted marketing access to Fujirebio Diagnostics, Inc.’s blood test to diagnose.

by HealthQuill
May 18, 2025
0 Comments

The US Food and Drug Administration has approved Britain’s GSK Plc’s drug to treat urinary tract infections in adult women and girls above 12 years, according to the company.

Drugs Medical Pharma

GSK’s drug to fight urinary tract infections gets USFDA approval

HQ Team March 26, 2025: The US Food and Drug Administration has approved Britain’s GSK Plc’s drug to treat urinary tract infections in.

by HealthQuill
March 26, 2025
0 Comments

Drugs Health Pharma

Eli Lilly cuts price of weight-loss drug Zepbound to take on copycats

Eli Lilly and Company cut the prices of its weight-loss drug Zepbound, available in single-dose vials, in a bid to end compounding companies from.

by HealthQuill
February 25, 2025
0 Comments

Regeneron Pharmaceuticals, Inc.’s investigational gene therapy improved hearing in 10 out of 11 children born with hearing loss because of gene mutation, according to a company statement.

Drugs Health Medical

Regeneron’s trial therapy improves hearing in children with gene mutations

Regeneron Pharmaceuticals, Inc.’s investigational gene therapy improved hearing in 10 out of 11 children born with hearing loss because of gene mutation, according.

by HealthQuill
February 25, 2025
0 Comments

Ireland’s Medtronic Plc’s deep brain stimulation device for patients with Parkinson’s disease has been approved by the US Food and Drug Administration, according to a company statement.

Health Medical Pharma

Medtronic Plc’s neurostimulator for Parkinson’s gets USFDA approval

Ireland’s Medtronic Plc’s deep brain stimulation device for patients with Parkinson’s disease has been approved by the US Food and Drug Administration, according.

by HealthQuill
February 24, 2025
0 Comments

FibroGen Inc., a US-based pharmaceutical company, will sell its China subsidiary to AstraZeneca Plc. for $160 million, allowing the Anglo-Swedish firm to gain access to an anaemia drug in the world’s most populated nation.

Drugs Health Pharma

AstraZeneca Plc buys China unit of FibroGen Inc for $160 million

HQ Team February 21, 2025: FibroGen Inc., a US-based pharmaceutical company, will sell its China subsidiary to AstraZeneca Plc. for $160 million, allowing.

by HealthQuill
February 21, 2025
0 Comments

Merck & Co. halted its final-phase study of its experimental drug for pulmonary arterial hypertension after previous studies proved its “robust efficacy,” according to a company statement.

Drugs Health Medical

Merck & Co stops final-stage drug trial for treating PAH

Merck & Co. halted its final-phase study of its experimental drug for pulmonary arterial hypertension after previous studies proved its “robust efficacy,” according.

by HealthQuill
January 30, 2025
0 Comments

The US drug regulator has put a clinical hold on Atara Biotherapeutics’ T-cell therapies for cancer and autoimmune diseases after issues were observed at a third-party manufacturing facility.

Drugs Health Medical Pharma

FDA places Atara’s Biothearapeutics’ cancer, autoimmune therapies on hold

The US drug regulator has put a clinical hold on Atara Biotherapeutics’ T-cell therapies for cancer and autoimmune diseases after issues were observed.